NCT06289504View on ClinicalTrials.gov

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

October 16, 2024

Study Completion Date

November 15, 2024

Conditions
Obesity
Interventions
DRUG

Cagrilintide

Cagrilintide will be administered subcutaneously once weekly.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously once weekly.

DRUG

Atorvastatin

Atorvastatin will be administered as a single dose orally 2 times during the study.

DRUG

Warfarin

Warfarin will be administered as a single dose orally 2 times during the study.

Trial Locations (1)

H3P 3P1

Altasciences Company Inc., Mount Royal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY